- C(sp3)-H Monoarylation of Methanol Enabled by a Bidentate Auxiliary
-
With the assistance of a practical directing group (COAQ), the first catalytic protocol for the palladium-catalyzed C(sp3)-H monoarylation of methanol has been developed, offering an invaluable synthesis means to establish extensive derivatives of crucial arylmethanol functional fragments. Furthermore, the gram-scale reaction, broad substrate scope, excellent functional group compatibility, and even the practical synthesis of medicines further demonstrate the usefulness of this strategy.
- Gou, Quan,Ran, Man,Ren, Jian,Tan, Xiaoping,Yuan, Binfang,Yuan, Tengrui,Zhang, Ming-Zhong,Zhang, Xing
-
supporting information
p. 118 - 123
(2021/01/13)
-
- THERAPEUTIC OR PROPHYLACTIC AGENT FOR LEUKEMIA
-
A therapeutic or prophylactic agent for leukemia is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for leukemia according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits prominent therapeutic or prophylactic effects.
- -
-
Page/Page column 26
(2009/04/23)
-
- THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DERMATITIS
-
A therapeutic or prophylactic agent for allergic dermatitis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for allergic dermatitis according to the present invention has high therapeutic or prophylactic effect.
- -
-
Page/Page column 25
(2009/04/23)
-
- THERAPEUTIC OR PROPHYLACTIC AGENT FOR MULTIPLE SCLEROSIS
-
A therapeutic or prophylactic agent for multiple sclerosis is disclosed. The therapeutic or prophylactic agent comprises as an effective ingredient a glycine derivative having a specific structure or a pharmaceutically acceptable salt thereof, for example, the below-described compound [(E)-2-(2,6-dichlorobenzamido)-5-[4-(isopropyl-pyrimidin-2-ylamino)phenyl]pent-4-enoic acid]. The therapeutic or prophylactic agent for multiple sclerosis according to the present invention shows the excellent absorbability and in vivo stability when orally administered, and exhibits high therapeutic or prophylactic effects.
- -
-
Page/Page column 25-26
(2009/04/23)
-
- GLYCINE DERIVATIVE AND USE THEREOF
-
The compounds in the present invention, for example, the compound represented by the formula: has an excellent therapeutic and prophylactic effects against inflammatory bowel disease. Further, they are excellent in absorption and in vivo stability when administered orally in comparison with conventional compounds. That is, the compounds can be administered orally, and can have excellent therapeutic or prophylactic effect sustained for a longer period of time.
- -
-
-
- GLYCINE DERIVATIVE AND USE THEREOF
-
A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in absorbability in oral administration and in vivo stability. The compound can be orally administered and can retain an excellent therapeutic or preventive effect over a longer period.
- -
-
Page/Page column 40-41
(2008/06/13)
-
- Pyrazolopyrimidines as therapeutic agents
-
The present invention is directed to pyrazolopyrimidine derivatives of formula (I) wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.
- -
-
-